Top-notch biotech stock Avidity collapsed Monday despite unveiling “positive” midstage test results for its muscular dystrophy treatment.

The post Top 2% Biotech Avidity Collapses Despite ‘Positive’ Results In Treating Muscular Dystrophy appeared first on Investor’s Business Daily.